Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totalling 97,900 shares, a decline of 6.6% from the July 31st total of 104,800 shares. Based on an average daily volume of 26,300 shares, the short-interest ratio is presently 3.7 days. Currently, 3.2% of the company’s stock are short sold.

Hedge Funds Weigh In On Eterna Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. CI Private Wealth LLC acquired a new position in shares of Eterna Therapeutics during the fourth quarter worth $197,000. Sippican Capital Advisors grew its stake in shares of Eterna Therapeutics by 60.0% during the second quarter. Sippican Capital Advisors now owns 21,601 shares of the company’s stock worth $49,000 after purchasing an additional 8,101 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Eterna Therapeutics during the fourth quarter worth $56,000. Geode Capital Management LLC acquired a new position in shares of Eterna Therapeutics during the fourth quarter worth $45,000. Finally, Goldman Sachs Group Inc. acquired a new position in Eterna Therapeutics in the second quarter valued at $26,000. Institutional investors and hedge funds own 6.04% of the company’s stock.

Eterna Therapeutics Trading Down 6.6 %

Shares of ERNA stock opened at $2.28 on Friday. The firm has a fifty day moving average price of $2.54 and a 200 day moving average price of $2.86. The company has a market cap of $12.33 million, a P/E ratio of -0.40 and a beta of 4.23. Eterna Therapeutics has a 12 month low of $1.90 and a 12 month high of $8.52.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.